Basilea has signed an asset purchase agreement with the Glioblastoma Foundation for the company’s glioblastoma candidate, lisavanbulin (BAL101553). Under the terms of the deal, Basilea will sell and transfer all rights for lisavanbulin to the charitable organisation for an undisclosed initial purchase cost. In the future, Basilea will continue to take part in any potential commercial partnerships at a fixed double-digit percentage.
The Glioblastoma Foundation plans to take over lisavanbuilin’s post-access trial programme, allowing patients from previous clinical studies to continue receiving the drug. The charity will also oversee any further clinical studies investigating the use of lisavanbulin in glioblastoma. The gold standard of business intelligence.
Lisavanbulin is a checkpoint inhibitor that binds to tubulin, which blocks the cell cycle and triggers cell death in cancer cells. The company was developing the drug for brain cancer, and the drug even received an US Food and Drug Administration orphan drug designation in 2021 for the treatment of malignant glioma, a type of brain cancer. However, after a disappointing Phase I/II trial (NCT02490800) readout, the Swiss pharmaceutical company decided not to expand the glioblastoma patient cohort for lisavanbulin in 2022.
In the open-label study of nine patients with measurable disease at stage one, one patient demonstrated a partial response to lisavanbulin whilst another showed a 44% target lesion area reduction, as per.